Need a new search?

If you didn't find what you were looking for, try a new search!

4 10, 2024

Webinar: The Technology Tuck-In: Insomnia Treatments

2024-11-06T10:25:00-06:00October 4th, 2024|

Insomnia continues to be a common sleep disorder affecting ~10% of adults, with ~20% experiencing occasional insomnia. It is often a chronic condition with a 40% persistence rate over a 5-year period. Members of the Emerging Technology Committee share non-pharmacologic treatments for insomnia. [...]

4 10, 2024

Staying current with insomnia-related technologies

2024-10-04T11:05:06-05:00October 4th, 2024|Montage|

By Shalini Paruthi, MD, FAASM; Steven Holfinger, MD, MS; Sachin Shah, MD, MS; Evin Jerkins, DO; Christine Won, MD; Sharon Schutte-Rodin, MD, FAASM; on behalf of the AASM Emerging Technology Committee Keeping up with diverse and numerous insomnia-related devices and products can be challenging [...]

13 09, 2024

Talking Sleep | Sleep-related anxiety and new-onset insomnia

2024-09-13T12:22:59-05:00September 13th, 2024|Talking Sleep|

Season 6 | Episode 18 DRS. LEISHA CUDDIHY, SARA NOWAKOWSKI, AND MICHAEL GRANDNER, GUESTS We have long known about the bi-directional relationship between anxiety and insomnia, and traditionally we’ve been taught that treating anxiety will treat insomnia. Since that time, more data have [...]

9 08, 2024

FDA clears SleepioRx for chronic insomnia

2024-09-24T14:26:34-05:00August 9th, 2024|Industry|

On Aug. 8, 2024, Big Health announced it received FDA clearance for its digital therapeutic, SleepioRx, for the treatment of chronic insomnia as an adjunct to usual care in adults. About SleepioRx SleepioRx is a prescription device that delivers cognitive behavioral therapy for [...]

19 07, 2024

Talking Sleep | Sleep technology for insomnia

2024-08-02T08:39:54-05:00July 19th, 2024|Talking Sleep|

Season 6 | Episode 14 DRS. SHALINI PARUTHI AND SACHIN SHAH, GUESTS As technology continues to permeate every aspect of our lives, the subset of sleep-related technology continues to expand. The AASM Emerging Technology committee continues to assess both clinical and consumer sleep [...]

24 06, 2024

Insomnia Toolkit for Clinicians

2024-06-28T09:03:16-05:00June 24th, 2024|

Insomnia Toolkit for Clinicians Insomnia disorder is associated with substantial burden that impacts patients, providers, payers, health systems, and society at large. As a foundational step toward improving access to high-quality insomnia care, the American Academy of Sleep Medicine (AASM) convened key stakeholders [...]

19 03, 2024

Somnio Online Insomnia Therapy

2024-03-19T16:15:07-05:00March 19th, 2024|Sleep Technology Assessment|

Summary Somnio Insomnia Therapy is an online, self-directed, 8-session course focused on improving the user’s sleep pattern and sleep environment, identifying and adjusting lifestyle habits, learning to recognize and change negative beliefs and thoughts, reinforcing positive beliefs and thoughts, and learning techniques that help [...]

1 11, 2023

FDA clears Modius Sleep device for chronic insomnia

2024-09-24T21:05:22-05:00November 1st, 2023|Industry|

Neurovalens announced Oct. 31 it has received FDA 510(k) clearance for its Modius Sleep device intended to treat chronic insomnia. By delivering a small and safe electrical pulse to the head for 30 minutes before bed, Modius Sleep is designed to improve insomnia. [...]

24 02, 2023

Talking Sleep | Comorbid insomnia and sleep apnea (COMISA)

2023-09-06T14:45:36-05:00February 24th, 2023|Talking Sleep|

Talking Sleep Season 5 | Episode 4 Comorbid insomnia and sleep apnea (COMISA) Dr. Alexander Sweetman, GUEST An article published in ERJ Open Research demonstrates that cognitive behavioral therapy for insomnia (CBT-I) consolidates sleep periods and promotes a 15% decrease in OSA severity [...]

11 01, 2022

Idorsia receives FDA approval of QUVIVIQ for insomnia

2024-09-24T21:57:42-05:00January 11th, 2022|Industry|

On Jan. 10, 2022, Idorsia announced that the FDA approved QUVIVIQ (daridorexant) 25 mg and 50 mg for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. About QUVIVIQ QUVIVIQ is a prescription medication indicated for [...]

5 08, 2021

New Clinical Practice Guideline Supports Behavioral, Psychological Treatments for Insomnia

2021-08-10T08:26:59-05:00August 5th, 2021|Montage|

By Jack Edinger, PhD, Chair, Behavioral and Psychological Treatments for Insomnia Guideline Task Force Chronic insomnia disorder is a widespread and debilitating condition that affects quality of life, daytime functioning, mental and physical health, and health care utilization for millions worldwide. The International Classification [...]

16 12, 2020

New guideline supports behavioral, psychological treatments for insomnia

2020-12-16T11:14:33-06:00December 16th, 2020|Clinical Resources, Featured, Patient Information, Press Releases|

DARIEN, IL – The American Academy of Sleep Medicine has published a new clinical practice guideline establishing recommendations for the use of behavioral and psychological treatments for chronic insomnia disorder in adults. The guideline includes one strong recommendation — which is one that clinicians [...]

23 09, 2020

Study shows weighted blankets can decrease insomnia severity

2020-11-09T10:49:30-06:00September 23rd, 2020|Featured, Press Releases|

DARIEN, IL – Weighted blankets are a safe and effective intervention in the treatment of insomnia, according to Swedish researchers who found that insomnia patients with psychiatric disorders experienced reduced insomnia severity, improved sleep and less daytime sleepiness when sleeping with a weighted chain [...]

15 05, 2020

AASM invites public comment on the draft guideline for behavioral treatments for chronic insomnia disorder in adults

2020-06-08T08:25:32-05:00May 15th, 2020|Clinical Resources, Patient Information|

The American Academy of Sleep Medicine (AASM) is inviting public comment on drafts of a clinical practice guideline on the Behavioral and Psychological Treatments for Chronic Insomnia Disorder in Adults and accompanying systematic review. The public comment period is open for 4 weeks [...]

26 03, 2020

Digital treatment for insomnia receives FDA clearance

2020-03-26T22:32:34-05:00March 26th, 2020|Industry|

The U.S. Food and Drug Administration has cleared the first prescription-based digital therapeutic for the treatment of chronic insomnia in adults, according to a press release from the product developer, Pear Therapeutics. Somryst, formerly SHUTi, uses cognitive behavioral therapy and data-based sleep restrictions to [...]

7 02, 2020

FDA updates insomnia medication info to include Alzheimer’s study

2020-02-07T16:09:39-06:00February 7th, 2020|Industry|

Merck announced Feb. 3, 2020, that the U.S. Food and Drug Administration has updated the prescribing information for Belsomra (suvorexant) to include details about an insomnia study in patients with mild to moderate Alzheimer’s disease. Belsomra was first FDA-approved for the treatment of insomnia [...]

13 09, 2019

Insomnia in Children Health Advisory

2019-09-16T19:23:45-05:00September 13th, 2019|

Insomnia in Children Health Advisory Behavioral interventions should be the first treatment option for healthy children who struggle with bedtime resistance or nighttime awakenings. For those who fail to respond, or for children with more complex medical problems, evaluation by a sleep physician [...]

Go to Top